Emerging Opportunities in Cancer Nucleic Acid Testing

Date: February 14, 2012
Pages: 45
Price:
US$ 1,450.00 US$ 1,232.50
License [?]:
Publisher: VPGMarketResearch.com
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7DFB2CEE2BEN
Leaflet:

Download PDF Leaflet

Emerging Opportunities in Cancer Nucleic Acid Testing
The report presents an overview of the clinical significance and market needs for major tumor markers, as well as listings of companies developing and marketing NAT technologies and products for cancer testing.

Contains 45 pages
1. OVERVIEW

2. MAJOR CANCER TYPES


Prostate
Lung
Colon and Rectum
Breast
Skin
Uterine
Leukemia
Oral

3. ONCOGENES

Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src

TABLES

Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
Skip to top


Ask Your Question

Emerging Opportunities in Cancer Nucleic Acid Testing
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: